p53 Expression in colorectal cancer: Relation to tumor type, DNA ploidy pattern, and short-term survival

American Journal of Clinical Pathology

Volumn 105, Issue 5, 1996, Pages 604-612

  Lanza Jr , Giovanni ^a   Maestri, Iva ^a   Dubini, Alessandra ^a   Gafa', Roberta ^a   Santini, Alessandra ^b   Ferretti, Stefano ^a   Cavazzini, Luigi ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b S ANNA HOSPITAL   (Italy)

Author keywords

Colorectal cancer; DNA ploidy; Flow cytometry; Immunohistochemistry; Mucinous carcinoma; p53 protein; Prognosis

Indexed keywords

CELL NUCLEUS DNA; MONOCLONAL ANTIBODY KI 67; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0029985940     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.5.604     Document Type: Article

References (57)

1. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878.
2. Levine AJ, Perry ME, Chang A, et al. The role of the JKJ53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-416.
3. Soussi T, Legros V, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: A review. Int J Cancer 1994;57:1-9.
4. Goh H-S, Chan C-S, Khine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994;344:233-234.
5. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-48.
6. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990;50:7717-7722.
7. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992;52:3965-3971.
8. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-562.
9. Yamaguchi A, Nakagawara G, Kurosaka Y, et al. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993;68:399-402.
10. Auvinen A, Isola J, Visakorpi T, et al. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994;70: 293-296.
11. Scott N, Sagar P, Stewart J, et al. p53 in colorectal cancer: Clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-319.
12. O'Connell MJ, Schaid DJ, Ganju V, et al. Current status of adjuvant chemotherapy for colorectal cancer: Can molecular markers play a role in predicting prognosis? Cancer 1992;70:1732-1739.
13. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
14. Meling GI, Lothe RA, Borresen A-L, et al. The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. Br J Cancer 1993;67:93-98.
15. Hermanek P, Sobin LH, eds. UICC TNM Classification of Malignant Tumours. ed 4. Berlin: Springer-Verlag, 1987, pp 47-49.
16. Jass JR, Sobin LH. Histological typing of intestinal tumours. World Health Organization. International Histological Classification of Tumours. ed 2. Berlin: Springer-Verlag, 1989, pp 32-33.
17. Jass JR, Atkin WS, Cuzick J, et al. The grading of rectal cancer: Historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-459.
18. Lanza G Jr, Cavazzini L, Borghi L, et al. Immunohistochemical assessment of growth fractions in colorectal adenocarcinomas with monoclonal antibody Ki-67: Relation to clinical and pathological variables. Path Res Pract 1990;186:608-618.
19. Lanza G Jr, Maestri I, Ballotta MR, Dubini A, Cavazzini L. Relationship of nuclear DNA content to clinicopathologic features in colorectal cancer. Mod Pathol 1994;7:161-165.
20. Hiddemann W, Schumann J, Andreef M, et al. Convention on nomenclature for DNA cytometry. Cancer Genet Cytogenet 1984;13:181-183.
21. Lee E, Desu M. A computer program for comparing k samples with right censored data. Comput Programs Biomed 1972;2: 315-320.
22. Baas IO, Mulder J-WR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
23. Costa A, Marasca R, Valentinis B, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
24. Cripps KJ, Purdie CA, Carder PJ, et al. A study of stabilisation of p53 protein versus point mutation in colorectal carcinoma. Oncogene 1994;9:2739-2743.
25. Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer 1994;70:585-590.
26. Bertorelle R, Esposito G, Del Mistro A, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995;19:463-471.
27. Hall PA, Lane DP. p53 in tumour pathology: Can we trust immunohistochemistry? Revisited! J Pathol 1994;172:1-4.
28. Campo E, de la Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Res 1991;51:4436-4442.
29. Purdie CA, O'Grady J, Piris J, Wyllie AH, Bird CC. p53 expression in colorectal tumors. Am J Pathol 1991;138:807-813.
30. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52: 1974-1980.
31. Kawasaki Y, Monden T, Morimoto H, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol 1992;97:244-249.
32. Yamaguchi A, Kurosaka Y, Fushida S, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-2784.
33. Sun X-F, Carstensen JM, Zhang H, et al. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-1373.
34. Bosari S, Viale G, Bossi P, et al. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 1994;86:681-687.
35. Zeng Z-S, Sarkis AS, Zhang Z-F, et al. p53 nuclear overexpression: An independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-2050.
36. Mulder J-WR, Baas IO, Polak MM, Goodman SN, Offerhaus GJA. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995;71: 1257-1262.
37. Ofner D, Maier H, Riedmann B, et al. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: Prognostic significance. J Clin Pathol: Mol Pathol 1995;48:M12-M16.
38. Hanski C, Bornhoeft G, Shimoda T, et al. Expression of p53 protein in invasive colorectal carcinomas of different histologic types. Cancer 1992;70:2772-2777.
39. Heimann TM, Oh SC, Martinelli G, et al. Colorectal carcinoma associated with ulcerative colitis: A study of prognostic indicators. Am J Surg 1992;164:13-17.
40. Connell WR, Talbot IC, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994;35:1419-1423.
41. Mecklin J-P, Sipponen P, Jarvinen HJ. Histopathology of colorectal carcinomas and adenomas in cancer family syndrome. Dis Colon Rectum 1986;29:849-853.
42. Symonds DA, Vickery AL Jr. Mucinous carcinoma of the colon and rectum. Cancer 1976;37:1891-1900.
43. Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987;11:259-272.
44. Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: A multivariate analysis. J Clin Pathol 1988;41:1068-1072.
45. Laurent-Puig P, Olschwang S, Delattre O, et al. Association of Ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. Int J Cancer 1991;49:220-223.
46. Heerdt BG, Molinas S, Deitch D, Augenlicht LH. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene 1991;6:125-129.
47. Kern SE, Fearon ER, Tersmette KWF, et al. Allelic loss in colorectal carcinoma. JAMA 1989;261:3099-3103.
48. Delattre O, Olschwang S, Law DJ, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989;ii: 353-356.
49. Offerhaus GJA, De Feyter EP, Cornelisse CJ, et al. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma. Gastroenterology 1992;102:1612-1619.
50. Remvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-764.
51. Carder P, Wyllie AH, Purdie CA, et al. Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 1993;8:1397-1401.
52. De Angelis P, Stokke T, Smedshammer L, et al. p53 expression is associated with a high degree of tumor DNA aneuploidy and incidence of p53 gene mutation, and is localized to the aneuploid component in colorectal carcinomas. Int J Oncol 1993;3: 305-312.
53. Carder PJ, Cripps KJ, Morris R, et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995;71:215-218.
54. Rognum TO, Thorud E, Lund E. Survival of large bowel carcinoma patients with different DNA ploidy. Br J Cancer 1987;56: 633-636.
55. Bufill JA. Colorectal cancer: Evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-788.
56. Giaretti W, Santi L. Tumor progression by DNA flow cytometry in human colorectal cancer. Int J Cancer 1990;45:597-603.
57. Harlow SP, Eriksen BL, Poggensee L, et al. Prognostic implications of proliferative activity and DNA aneuploidy in Astler-Coller Dukes stage C colonic adenocarcinomas. Cancer Res 1991;51: 2403-2409.